Clonal heterogeneity by fluorescence in situ hybridization in multiple myeloma: enhanced cytogenetic risk stratification

Egyptian Journal of Medical Human Genetics

Table 3 The association between treatment response and risk stratification with cytogenetic aberrations

	Non-responders	Responders	Test value	P value	Sig.
	No. = 21	No. = 39	Test value	P value	Sig.
FISH
Negative	4 (19.0%)	11 (28.2%)	0.611	0.434	NS
Hyperdiploidy	2 (9.5%)	19 (48.7%)	9.217	0.002	HS
t(4;14)	3 (14.3%)	3 (7.7%)	0.659	0.417	NS
del13q	3 (14.3%)	1 (2.6%)	3.014	0.083	NS
t(11;14)	2 (9.5%)	2 (5.1%)	0.424	0.515	NS
del17p	7 (33.3%)	0 (0.0%)	14.717	0.000	HS
14q	0 (0.0%)	3 (7.7%)	1.700	0.192	NS
Risk stratification
Standard risk	8 (38.1%)	33 (84.6%)	14.310*	0.001	HS
Intermediate risk	6 (28.6%)	4 (10.3%)
High risk	7 (33.3%)	2 (5.1%)

FISH fluorescence in situ hybridization
*Chi-square test
P value > 0.05: non-significant; P value < 0.05: significant (bold); P value < 0.01: highly significant